Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONVERT: Arikayce in Refractory MAC Lung Disease
NCT02344004Phase 3Completed
- Sponsor
- Insmed Incorporated
- Start
- May 2015
- Primary completion
- Jul 2018
- Modality
- Small Molecules, Lipid-based Nanoparticles
01
Overview
Phase 3, randomised, open-label trial of amikacin liposome inhalation suspension in Mycobacterium avium complex lung infection (2 arms), sponsored by Insmed Incorporated. Primary endpoints: Number of Participants Achieving Culture Conversion at Month 6 and Number of Participants Achieving Durable Culture Conversion Through 3 Months Off Treatment. Started May 2015; status: completed.
02
Drugs
amikacin liposome inhalation suspension
03
Conditions
Mycobacterium avium complex lung infection
Beyond the preview
Go deeper on NCT02344004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02344004.